Market Overview

Sarcopenia is the loss of skeletal muscle mass and function occurs with advancing age. Rising geriatric population is one of the key drivers of the studied market, as with growing age the chance of muscle weakness gets increased. The risk of disability is 1.5 to 4.6 times higher in older adults with sarcopenia than older adults without sarcopenia. In accordance with the data from World Population Prospects: the 2019 Revision, by 2050, 1 in 6 people in the world will be over age 65 (16%), up from 1 in 11 in 2019 (9%) and by 2050, 1 in 4 persons living in Europe and Northern America could be aged 65 or over. In 2018, the persons aged 65 or above outnumbered children under five years of age globally. The number of persons aged 80 years or over is projected to triple, from 143 million in 2019 to 426 million in 2050. This rising aging population trend hence holds the maximum potential to drive the market in the near future also.

Scope of the Report

Sarcopenia is a term used to describe the loss of muscle mass, strength, and function that is associated with aging. Currently, there are no FDA-approved medications for the treatment of sarcopenia. The effects of exercise and nutritional supplementation on patients with sarcopenia have been examined in numerous studies. In this report, the supplements (protein, vitamins, and others) for treating sarcopenia, therefore, have been considered.

Key Market Trends

Protein Supplement is anticipated to grow with Considerable CAGR during Forecast Periods

Nutrition supplementation along with exercise is an effective strategy to decrease all the macronutrients that can be used for energy production in the human body, but only protein serves as a structural and functional compound in all organs and cells, which is why its demand is likely to increase in future. Proteins, especially rich in leucine, are the most effective branched-chain amino acid at stimulating muscle protein synthesis. Protein supplements help to retain muscle mass muscle strength and endurance. Recent evidence by Anne-Julie Tessier et al. supports a higher protein intake recommendation of 1.0–1.2 g/kg/day in healthy older adults; an evenly distributed mealtime protein intake or minimal protein per meal is considered to be beneficial.

North America Dominates the Global Sarcopenia Treatment Market

As per the Population Reference Bureau, the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16% to 23%. About 45% of older adults in the United States are affected by sarcopenia, which is expected to increase as the population ages. In addition, there is a considerable economic burden of related healthcare expenditures for sarcopenia in the United States which is estimated to be USD 18.5 billion annually. Furthermore, the health awareness and active presence of major players are likely to drive the studied market growth in this region.

Competitive Landscape

The key manufacturers in the sarcopenia treatment market have been focusing on novel marketing and sales strategies to increase their product penetration. Along with that, rising inclination towards online distribution channel have been playing a vital role. Few of the key market players in the studied market are GlaxoSmithKline plc, Eli Lilly and Company, Nestl? S.A., Sanofi S.A., Bayer AG among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support